GlassScriptPhysician profile
Desmond Adamu
NPI 1477996585
$4,340.63
in general payments reported to CMS, 2019-2025
24 companies · $651 in 2025
The $651 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $599 · 2020: $285 · 2021: $294 · 2022: $153 · 2023: $2,004 · 2024: $356 · 2025: $651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,530 · Travel and Lodging: $1,255 · Education: $226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,530.22 |
| Travel and Lodging | $1,254.83 |
| Education | $225.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,390.86 | 2023-2025 | Interstim |
| Boston Scientific Corporation | $649.05 | 2019-2025 | Ams 700, Ams 700 Cxr Rte Kit, Rezum Generator |
| Astellas Pharma US INC | $421.99 | 2019-2024 | Xtandi |
| Procept Biorobotics Corporation | $346.43 | 2025 | |
| Pfizer INC. | $285.07 | 2019-2021 | |
| Janssen Biotech, INC. | $271.35 | 2022-2025 | Erleada, Akeega |
| Coloplast Corp | $239.17 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $153.46 | 2023-2024 | Gemtesa, Orgovyx |
| Kci USA, INC. | $125.00 | 2019 | |
| Myriad Genetic Laboratories, INC. | $117.92 | 2024-2025 | Prolaris |
| Abbvie INC. | $49.50 | 2021 | |
| Astellas Pharma Global Development | $42.45 | 2024-2025 | Xtandi |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Axonics, INC. | $28.79 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $24.88 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $23.77 | 2024 | Tisseel |
| Glaxosmithkline, LLC. | $20.50 | 2021 | |
| Blue Earth Diagnostics | $20.36 | 2022 | |
| Endo Pharmaceuticals INC. | $20.10 | 2019 | |
| Tolmar, INC. | $19.75 | 2023 | |
| Myovant Sciences INC. | $19.56 | 2021 | |
| Merck Sharp & Dohme LLC | $17.53 | 2022 | |
| Acera Surgical, INC. | $11.14 | 2019 | |
| Aroa Biosurgery Incorporated | $6.94 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Desmond Adamu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.